Citigroup Inc Surmodics Inc Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Surmodics Inc stock. As of the latest transaction made, Citigroup Inc holds 22,011 shares of SRDX stock, worth $869,874. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,011

Previous 16,335 34.75%

Holding current value

$869,874

Previous $686,000 24.34%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$38.47 - $42.24 $218,355 - $239,754	5,676 Added 34.75%	22,011 $853,000
Q2 2024 Aug 12, 2024	BUY	$25.39 - $42.1 $356,120 - $590,494	14,026 Added 607.45%	16,335 $686,000
Q1 2024 May 10, 2024	BUY	$27.44 - $35.56 $9,247 - $11,983	337 Added 17.09%	2,309 $67,000
Q4 2023 Feb 09, 2024	BUY	$28.47 - $38.49 $54,690 - $73,939	1,921 Added 3766.67%	1,972 $71,000
Q3 2023 Nov 09, 2023	SELL	$28.28 - $38.36 $115,750 - $157,007	-4,093 Reduced 98.77%	51 $1,000
Q2 2023 Aug 10, 2023	BUY	$17.67 - $31.31 $66,704 - $118,195	3,775 Added 1023.04%	4,144 $129,000
Q1 2023 May 11, 2023	SELL	$17.13 - $38.52 $137,416 - $309,007	-8,022 Reduced 95.6%	369 $8,000
Q4 2022 Feb 09, 2023	BUY	$29.44 - $37.31 $51,431 - $65,180	1,747 Added 26.29%	8,391 $286,000
Q3 2022 Nov 10, 2022	BUY	$28.84 - $38.92 $14,737 - $19,888	511 Added 8.33%	6,644 $202,000
Q2 2022 Aug 10, 2022	SELL	$33.25 - $45.11 $195,244 - $264,885	-5,872 Reduced 48.91%	6,133 $228,000
Q1 2022 May 12, 2022	BUY	$40.68 - $49.72 $56,545 - $69,110	1,390 Added 13.09%	12,005 $544,000
Q4 2021 Feb 10, 2022	BUY	$43.21 - $57.6 $141,383 - $188,467	3,272 Added 44.56%	10,615 $511,000
Q3 2021 Nov 10, 2021	BUY	$52.8 - $60.32 $387,710 - $442,929	7,343 New	7,343 $409,000

Others Institutions Holding SRDX

# of Institutions

127

Shares Held

11.8M

Call Options Held

1.4K

Put Options Held

8.6K

View Full List

About SURMODICS INC

Ticker SRDX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 14,005,000
Market Cap $553M
Description
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device s...

More about SRDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account